68Ga-NI-FAPI PET/CT: First-in-human Study
Recruiting
Early Phase 1
Interventional Study
Malignant Neoplasm
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 40 (estimated)
- Sponsor
- First Affiliated Hospital of Fujian Medical University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
68Ga-NI-FAPI is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole (NI)-moiety and a FAP-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-NI-FAPI PET/CT in patients with different types of cancer.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Various solid tumors with available histopathological findings
* Signed informed consent
Exclusion Criteria:
* pregnant or lactational women
* who suffered from severe hepatic and renal insufficiency
Contacts